Hair Loss for Men: What's Actually Happening, and What Actually Works

By the time you see a clear part line, the hair follicles next to it have been miniaturizing for years. Thats the reason most men show up to my practice asking the same question: am I too late? The honest answer for most men in their 20s, 30s, and 40s is no. But the longer you wait, the more we are working to hold the line rather than grow new ground. So lets walk through whats happening, what works, and what to do this week.

What is actually causing the loss?

Male pattern hair loss (androgenetic alopecia, or AGA) is a genetically driven condition. Two things are required:

1. Inherited follicle sensitivity to DHT (dihydrotestosterone), a metabolite of testosterone.
2. A normal amount of DHT circulating in the body. You dont need high testosterone or high DHT for this. You just need follicles that are sensitive to it.

DHT is produced when testosterone is converted by an enzyme called 5-alpha reductase. On the scalp, in genetically sensitive follicles, DHT shortens the growth phase of each hair cycle. Over many cycles, the follicle miniaturizes. The hair gets thinner, finer, lighter, and eventually stops producing visible shaft. The follicle is still alive in early stages, which is why early intervention matters so much. The pattern matters too. Pattern loss usually starts at the temples and crown (a Norwood scale 2 or 3), with the donor area at the back and sides spared because those follicles arent DHT-sensitive. Diffuse thinning across the entire scalp is a different pattern and points to a different workup.

Get the workup before you assume its pattern loss

About one in five men I see for "hair loss" has something else going on, or pattern loss layered on top of something else. The labs we run first:

• TSH and free T4 to screen for thyroid disease. Both hypo- and hyperthyroidism can cause hair shedding.
• Ferritin (the iron storage protein). Even when hemoglobin looks normal, low ferritin (under 50 ng/mL is suboptimal for hair, under 30 is frankly low) is a common driver of telogen effluvium.
• 25-OH vitamin D. Deficiency is associated with poorer hair density in studies, and it is easy to fix.
• Total and free testosterone, plus estradiol. Especially if youre considering DHT-modulating therapy, the baseline matters.
• CBC and CMP as a general screen, and HbA1c if metabolic risk is in the picture.

We add antinuclear antibody (ANA) or other autoimmune work if the pattern looks like alopecia areata or a scarring alopecia. Those are very different conditions and require dermatology referral, not the AGA playbook. If the lab work flags one of the above, we treat the upstream issue first. Sometimes that alone restores the shedding and we never need to start AGA medications.

The FDA-approved treatments that actually work

The evidence base for AGA is one of the better-built bodies of research in dermatology. Two medications carry the load.

Finasteride (oral, 1 mg daily)

Finasteride is a 5-alpha reductase type 2 inhibitor. It blocks the conversion of testosterone to DHT at the follicle. In randomized trials, daily oral finasteride at 1 mg slows hair loss in about 90% of men and produces visible regrowth in roughly two-thirds, with peak effect at 12 to 24 months. It is FDA-approved for male pattern hair loss in men. It is a generic, very inexpensive medication, and we prescribe it directly through your local pharmacy. The full effect takes time. Most men see stabilization in 3 to 6 months and meaningful regrowth at 12 to 18 months.

Minoxidil (topical 5% twice daily, or oral low-dose)

Minoxidil works through a different mechanism: it improves blood flow to the follicle, prolongs the growth phase, and helps follicles produce thicker shafts. It is FDA-approved as a topical (5% solution or foam, applied twice daily). In the last few years, low-dose oral minoxidil has emerged as an alternative for men who dont tolerate the topical (scalp irritation, the daily routine, the visible residue at the part line). Doses of 2.5 to 5 mg daily are increasingly used off-label by dermatology and primary care physicians comfortable with the side effect profile (mild lower-extremity edema, possible body hair growth, occasional cardiovascular effects requiring monitoring). Finasteride and minoxidil work through different mechanisms, and combining them outperforms either alone in most studies. For men committed to the treatment, the standard protocol is both.

Where topical finasteride fits

Compounded topical finasteride is an option for men concerned about the systemic side effects of the oral form. It delivers the active ingredient directly to the scalp, in theory limiting systemic absorption. The evidence base is smaller than for oral, and the compounding pharmacy quality varies. When patients ask, we discuss the trade-off honestly: less systemic exposure, less data, more variability in the product itself.

The sexual side effect question

Finasteride has a real side effect profile, and it deserves a direct conversation rather than a brush-off. In randomized trials, the rate of reported sexual side effects (decreased libido, erectile difficulty, ejaculatory volume changes) at 1 mg daily is roughly 1-2% above placebo. Most studies show those side effects resolve when the medication is stopped. A small subset of patients describe persistent symptoms after discontinuation, sometimes called post-finasteride syndrome (PFS). The biology is still being studied; the existence of a discrete syndrome is debated, and the risk appears low but real. In my practice, the conversation looks like this:

• If you have baseline sexual dysfunction, anxiety about sexual side effects, or strong feelings about the topic, we may start with topical finasteride or minoxidil monotherapy.
• If you tolerate oral finasteride without issue at 6 weeks, the long-term data is reassuring.
• If something feels different at any point, we stop, reassess, and find another path. We do not push through symptoms.

The decision is yours. My job is to make sure you have the actual numbers, not a marketing pitch in either direction.

What we do not prescribe

A few things you may see online that we do not offer:

• Compounded peptides marketed for hair (GHK-Cu injectables, "hair peptides" sold by research-chemical sites). State medical boards prohibit physician prescribing of non-FDA-approved peptides. We do not provide them or guide their use.
• Proprietary "hair growth" supplement stacks with dozens of ingredients and no head-to-head data. We use individual targeted nutrients (vitamin D, iron) when your labs show a gap, not a generic stack.
• Expensive in-office treatments without evidence parity (some PRP protocols, certain laser caps). PRP has modest evidence and we discuss it when a patient asks, but it is not a first move.

The lifestyle layer

The medications do most of the work, but the foundation underneath matters more than most clinics admit.

• Sleep. Chronic short sleep increases cortisol, which can worsen telogen effluvium and undercut the response to AGA medications.
• Stress. Major life stress (job change, divorce, grief, severe illness) can trigger a months-long shedding event called acute telogen effluvium. The hair grows back, but the timing of recovery depends on the underlying nervous system load.
• Protein intake. Hair is structural protein; chronically under-eating protein (below 1.2 g/kg/day in active adults) can drag on regrowth.
• Smoking. Strongly associated with accelerated hair loss in observational data, likely through follicular microcirculation effects. One of the more under-discussed lifestyle factors.
• GLP-1 medications and weight loss. Rapid weight loss of any kind, including from GLP-1 therapy, can trigger telogen effluvium 2 to 3 months in. We watch for it and adjust the plan when it shows up.

Guidance from the clinic

"Most men ask me if its too late. The honest answer is that the regrowth potential is highest in the first 5 years after the loss starts, but the holding-the-line potential is good for much longer. The right time to start is when you decide its worth doing, not after you have measured every other option for another year."

Actionable Steps in Philly

Book Your Warm Invitation Call

Scientific References

1. Kaufman KD, et al. "Finasteride in the Treatment of Men With Androgenetic Alopecia." J Am Acad Dermatol. 1998.
2. Olsen EA, et al. "A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men." J Am Acad Dermatol. 2002.
3. Randolph M, Tosti A. "Oral Minoxidil Treatment for Hair Loss: A Review of Efficacy and Safety." J Am Acad Dermatol. 2021.
4. Hirshburg JM, et al. "Adverse Effects and Safety of 5-Alpha Reductase Inhibitors (Finasteride, Dutasteride): A Systematic Review." J Clin Aesthet Dermatol. 2016.
5. Trink A, et al. "A Randomized, Double-Blind, Placebo- and Active-Controlled, Half-Head Study to Evaluate the Effects of Platelet-Rich Plasma on Alopecia Areata." Br J Dermatol. 2013.

---

Medical Disclaimer: This resource provides clinical context for educational purposes. In the world of Precision Medicine, there is no "one size fits all"; the right treatment plan must be matched to your unique lab work, physiology, and goals. Consult Dr. Ash to determine if this approach is right for you, especially if you have chronic health conditions or are taking prescription medications.